Results 171 to 180 of about 3,280,705 (273)
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are characterized by drug‐resistant seizures and developmental slowing/regression. We examined the efficacy and tolerability of fenfluramine (FFA) in pediatric and adult patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and other DEEs.
Vicente Villanueva +29 more
wiley +1 more source
Abstract Objective Ketogenic dietary therapies can reduce seizure frequency in drug‐resistant epilepsy, but adherence to the classical ketogenic diet is often poor. Intermittent fasting supplemented with medium‐chain triglycerides (MCTs) may offer a more feasible and less restrictive alternative.
Wiebke Hahn +11 more
wiley +1 more source
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer +7 more
wiley +1 more source
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are associated with high premature mortality and increased risk of sudden unexpected death in epilepsy (SUDEP). However, epidemiological data remain limited, particularly for specific syndromes such as Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and infantile epileptic ...
Pierludovico Moro +5 more
wiley +1 more source
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer +7 more
wiley +1 more source
Abstract Objective Using a Dutch insurance claims registry, we examine whether people with epilepsy have an increased risk of major ischemic cardiovascular events or death compared to people without epilepsy. We also assess whether this risk differs between users of enzyme‐modulating and non‐enzyme‐modulating antiseizure medications (ASMs).
Paola Vassallo +4 more
wiley +1 more source
Abstract The implantation effect refers to a transient reduction in seizure frequency following intracranial electrode insertion in patients with epilepsy, independent of therapeutic intervention. This retrospective study examined potential clinical and demographic predictors of the implantation effect in 51 patients who underwent ...
Shreyashish Roy‐Chowdhury +8 more
wiley +1 more source
Seizure forecasting: The long and winding road to clinical translation
Abstract Seizure forecasting has progressed from theoretical aspiration to a rapidly advancing research domain, yet clinical translation remains limited. Over the past decades, advances in algorithm development, chronic electroencephalography (EEG), wearable sensors, and the characterization of seizure cycles have demonstrated that seizure risk is not ...
Philippa J. Karoly +7 more
wiley +1 more source

